Abstract: The present invention includes a composition and method for decreasing Bacillus anthracis virulence or toxicity comprising: at least one inhibitor that decreases an expression of one or more host genes selected from G6pc, Rgs1, Fosl2, Hcar2, Cxcl2 and Cxcl3, or Serpine1 (PAI-1).

Abstract: The present invention includes a live, self-attenuated therapeutic vaccine, virus and methods of making and using the same, comprising: an isolated virus comprising a viral genome that expresses one or more viral antigens; and an artificial microRNA 30 (amiR-30) expression cassette inserted into a viral neuraminidase (NA) or a viral non-structural (NS) gene segment that expresses an amiR-30 that specifically inhibits the expression of a host gene essential for influenza virus replication in host cells.

Abstract: The present invention includes a live, self-attenuated therapeutic vaccine, virus and methods of making and using the same, comprising: an isolated virus comprising a viral genome that expresses one or more viral antigens; and an artificial microRNA 30 (amiR-30) expression cassette inserted into a viral neuraminidase (NA) or a viral non-structural (NS) gene segment that expresses an amiR-30 that specifically inhibits the expression of a host gene essential for influenza virus replication in host cells.

Abstract: The present invention includes a composition and method for decreasing Bacillus anthracis virulence or toxicity comprising: at least one inhibitor that decreases an expression of one or more host genes selected from G6pc, Rgs1, Fosl2, Hcar2, Cxcl2 and Cxcl3, or Serpine1 (PAM).

Abstract: The present invention includes a live attenuated virus and methods of making the same comprising an isolated virus comprising a viral genome that expresses one or more viral antigens; and one or more exogenous species-specific microRNAs inserted into the viral genome and expressed thereby, wherein the species-specific microRNAs are ubiquitously expressed in a viral target species cell but not in a viral propagation cell.

Abstract: The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.

Abstract: The present invention includes antigenic fusion proteins, nucleic acids encoding the fusion proteins and methods of making and using the same, wherein the fusion protein comprises three or more different influenza A ectodomains of Matrix Protein 2 (M2e); one or more stem regions of an influenza A hemagglutinin 2 (HA2) protein; and optionally an anthrax antigen, wherein the fusion protein is immunogenic across strains.

Abstract: The present invention includes an isolated antigen against influenza A and a method of making the same that includes an ectodomain of influenza A Matrix Protein 2 (M2e) and a stem region of an influenza A hemagglutinin 2 (HA2) protein and an adjuvant. The invention further includes formulating the antigen into an isolated immune response stimulating fusion protein and/or a vaccine.

Abstract: The present invention includes a composition for the targeted-delivery of small interference RNA against bacteria comprising: a detoxified bacterial protein toxin that comprises a highly positively charged region; and an siRNA that is specific to, and knocks-down expression of one or more genes related to one or more virulence factors of the bacteria, wherein the siRNA is bound to the highly positively charged region of the detoxified bacterial protein toxin.

Abstract: The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.

Abstract: The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.

Abstract: The present invention includes antigenic fusion proteins, nucleic acids encoding the fusion proteins and methods of making and using the same, wherein the fusion protein comprises three or more different influenza A ectodomains of Matrix Protein 2 (M2e); one or more stem regions of an influenza A hemagglutinin 2 (HA2) protein; and optionally an anthrax antigen, wherein the fusion protein is immunogenic across strains.

Abstract: The present invention includes a live attenuated virus and methods of making the same comprising an isolated virus comprising a viral genome that expresses one or more viral antigens; and one or more exogenous species-specific microRNAs inserted into the viral genome and expressed thereby, wherein the species-specific microRNAs are ubiquitously expressed in a viral target species cell but not in a viral propagation cell.

Abstract: The present invention includes an isolated antigen against influenza A and a method of making the same that includes an ectodomain of influenza A Matrix Protein 2 (M2e) and a stem region of an influenza A hemagglutinin 2 (HA2) protein and an adjuvant. The invention further includes formulating the antigen into an isolated immune response stimulating fusion protein and/or a vaccine.

Abstract: The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.

Abstract: The invention relates to novel DNA and protein vaccines against Clostridium botulinum. The DNA vaccine includes a DNA molecule that includes a first segment encoding a fragment of a heavy chain region of a Clostridium botulinum neurotoxin, wherein the first segment is codon-enhanced to improve expression of the isolated DNA molecule in a mammalian host, and preferably a second segment that encodes a secretion signal peptide. The chimeric protein of the present invention includes the secretion signal peptide linked N-terminal of the fragment of a heavy chain region of a Clostridium botulinum neurotoxin. Use of these materials to raise antibodies, and to impart resistance against Clostridium botulinum to a mammal is also disclosed.